DOCSLIB.ORG

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists a Review of Their Efficacy and Tolerability

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists a Review of Their Efficacy and Tolerability DIABETES TREATMENTS Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability ALAN J. GARBER, MD, PHD administration, is defined as the differ- ence in insulin secretory response from an oral glucose load compared with intra- venous glucose administration (6) argeting the incretin system has be- factors or rates of hypoglycemia are war- (Supplementary Fig. 1). come an important therapeutic ap- ranted. At present, many available treat- There are two naturally occurring T incretin hormones that play a role in the proach for treating type 2 diabetes. ments for type 2 diabetes fail to maintain Two drug classes have been developed: glycemic control in the longer term be- maintenance of glycemic control: glucose- glucagon-like peptide (GLP)-1 receptor cause of gradual disease progression as dependent insulinotropic polypeptide agonists and dipeptidyl peptidase 4 b-cell function declines. Where sulfony- and GLP-1, both of which have a short (DPP-4) inhibitors. Clinical data have lureas or thiazolidinediones (common half-life because of their rapid inactivation revealed that these therapies improve gly- oral antidiabetic drugs) are used, the risk by DPP-4 (7). In patients with type 2 di- cemic control while reducing body weight of hypoglycemia and weight gain can in- abetes, the incretin effect is reduced or, in (GLP-1 receptor agonists, specifically) and crease (1,2). The development of new some cases, absent (8). In particular, the systolic blood pressure (SBP) in patients therapies for the treatment of type 2 dia- insulinoptropic action of glucose-depen- with type 2 diabetes. Furthermore, in- betes that, in addition to maintaining gly- dent insulinotropic polypeptide is lost in cidence of hypoglycemia is relatively low cemic control, could reduce body weight patients with type 2 diabetes. However, it with these treatments (except when used and hypoglycemia risk (3,4), may help has been shown that, after administration in combination with a sulfonylurea) be- with patient management. Indeed, guide- of pharmacological levels of GLP-1, the in- cause of their glucose-dependent mecha- lines have been developed that support sulin secretory function can be restored in nism of action. There are currently two the consensus that blood pressure, weight this population (9), and thus GLP-1 has GLP-1 receptor agonists available (exena- reduction, and avoidance of hypoglycemic become an important target for research tide and liraglutide), with several more events should be targeted in type 2 dia- into new therapies for type 2 diabetes. currently being developed. This review betes management alongside glycemic tar- GLP-1 has multiple physiological ef- considers the efficacy and safety of both gets. For example, the American Diabetes fects that make it an attractive candidate the short- and long-acting GLP-1 receptor Association (ADA) defines multiple goals for type 2 diabetes therapy. It increases agonists. Head-to-head clinical trial data of therapy that include A1C ,7.0% and insulin secretion while inhibiting gluca- suggest that long-acting GLP-1 receptor SBP ,130 mmHg and no weight gain gon release, but only when glucose levels agonists produce superior glycemic con- (or, in the case of obese subjects, weight are elevated (6,10), thus offering the po- trol when compared with their short- loss) (5). In particular, incretin-based tential to lower plasma glucose while re- acting counterparts. Furthermore, these therapies (GLP-1 receptor agonists, spe- ducing the likelihood of hypoglycemia. long-acting GLP-1 receptor agonists were cifically) can help meet these new tar- Furthermore, gastric emptying is delayed generally well tolerated, with transient gets by offering weight reduction, (10) and food intake is decreased after nausea being the most frequently reported blood pressure reduction, and reduced GLP-1 administration. Indeed, in a 6- adverse effect. hypoglycemia in addition to glycemic week study investigating continuous Careful consideration should be given control. GLP-1 infusion, patients with type 2 di- to the selection of therapies for managing abetes achieved a significant weight loss type 2 diabetes. In particular, antidiabetic WHAT IS GLP-1?—The incretin of 1.9 kg and a reduction in appetite from agents that offer improved glycemic con- effect, responsible for 50–70% of total baseline compared with patients receiving trol without increasing cardiovascular risk insulin secretion after oral glucose placebo, where there was no significant ccccccccccccccccccccccccccccccccccccccccccccccccc change in weight or appetite (11). Preclini- cal studies reveal other potential benefits From the Molecular and Cellular Biology Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas. of GLP-1 receptor agonist treatment in Corresponding author: Alan J. Garber, [email protected]. individuals with type 2 diabetes, which This publication is based on the presentations at the 3rd World Congress on Controversies to Consensus in include the promotion of b-cell prolifera- Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this supplement were tion (12) and reduced b-cell apoptosis made possible in part by unrestricted educational grants from AstraZeneca, Boehringer Ingelheim, Bristol- Myers Squibb, Daiichi Sankyo, Eli Lilly, Ethicon Endo-Surgery, Generex Biotechnology, F. Hoffmann-La (13). These preclinical results indicate Roche, Janssen-Cilag, Johnson & Johnson, Novo Nordisk, Medtronic, and Pfizer. that GLP-1 could be beneficial in treating DOI: 10.2337/dc11-s231 patients with type 2 diabetes. However, The article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/ because native GLP-1 is rapidly inactivated dc11-s231/-/DC1. © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly and degraded by the enzyme DPP-4 and cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ has a very short half-life of 1.5 min (14), to licenses/by-nc-nd/3.0/ for details. achieve the clinical potential for native care.diabetesjournals.org DIABETES CARE, VOLUME 34, SUPPLEMENT 2, MAY 2011 S279 Long-acting GLP-1s: efficacy and tolerability GLP-1, patients would require 24-h ad- to 21.5% in patients with type 2 diabetes liraglutide in combination with metfor- ministration of native GLP-1 (15). Be- inadequately controlled on metformin min 6 sulfonylurea (23.24 kg with 1.8 cause this is impractical as a therapeutic with or without a sulfonylurea (20–24). mg liraglutide). Reductions in SBP were option for type 2 diabetes, it was neces- Across these studies, body weight was also observed across the trials (mean de- sary to develop longer-acting derivatives seen to decrease in a dose-dependent crease 22.1 to 26.7 mmHg) (27–32). of GLP-1. manner; treatment with 10 mg exenatide, Liraglutide was generally well toler- as an add-on to metformin, resulted in the ated, with only transient nausea experi- DEVELOPMENT OF DPP-4– greatest weight loss (22.8 kg) in patients enced toward the beginning of the RESISTANT GLP-1 RECEPTOR previously treated with metformin alone studies. The rate of minor hypoglycemia AGONISTS—Two classes of incretin- (21). Exenatide was generally well toler- was very low in these trials (incidence based therapy have been developed to ated, with mild-to-moderate gastrointesti- ranged from 0.03 to 0.6 events/patient/ overcome the clinical limitations of na- nal effects being the most common year with the different treatment groups tive GLP-1: GLP-1 receptor agonists (e.g., adverse effect (20–23). The number of pa- [excluding those using liraglutide in com- liraglutide and exenatide), which exhibit tients experiencing nausea peaked during bination with a sulfonylurea]). However, increased resistance to DPP-4 degradation the initial weeks of treatment (0–8 weeks) as seen in the exenatide trials, frequency and thus provide pharmacological levels but decreased thereafter. Rates of hypogly- of hypoglycemia increased slightly when of GLP-1, and DPP-4 inhibitors (e.g., sita- cemia were relatively low in these studies, liraglutide was used in combination with gliptin, vildagliptin, saxagliptin), which although frequency of hypoglycemia was a sulfonylurea (incidence of major hypo- reduce endogenous GLP-1 degradation, increased when exenatide was used in glycemia: 0.056 events/patient/year; minor thereby providing physiological levels of combination with a sulfonylurea (20). In- hypoglycemia: 1.2 events/patient/year with GLP-1. In this review, we focus on the deed, the summary of product character- 1.8 mg liraglutide in combination with GLP-1 receptor agonist class of incretin- istics for exenatide states that when metformin and a sulfonylurea). based therapies. The efficacy and tolera- exenatide is used in combination with a bility of the DPP-4 inhibitors have been sulfonylurea, consideration should be OVERVIEW OF GLP-1 reviewed elsewhere (16). Two GLP-1 recep- given to reducing the sulfonylurea dose RECEPTOR AGONISTS IN tor agonists are licensed at present in Eu- to reduce the risk of hypoglycemia (17). DEVELOPMENT—In addition to lir- rope, the U.S., and Japan: exenatide (Byetta, aglutide and exenatide, there are several Eli Lilly) (17) and liraglutide (Victoza, Novo Liraglutide once-weekly GLP-1 receptor agonists in Nordisk) (18). For the purposes of this re- Liraglutide is a GLP-1 analog that shares development: exenatide long-acting
Load more

Recommended publications
  • GLP-1 Receptor Agonists
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. GLP-1 Receptor Agonists Evidence Summary GLP-1 agonists are beneficial for patients with type 2 diabetes and obesity. Some evidence suggests benefits for Alzheimer’s disease. It is unclear whether it is beneficial for individuals without underlying metabolic disease. Semaglutide seems to be most effective for metabolic dysfunction, though liraglutide has more preclinical data for Alzheimer’s disease. Neuroprotective Benefit: Evidence from many preclinical studies and a pilot biomarker study suggest some neuroprotective benefits with GLP-1 agonists. However, whether they may be beneficial for everyone or only a subset of individuals (e.g. diabetics) is unclear. Aging and related health concerns: GLP-1 agonists are beneficial for treating diabetes and cardiovascular complications relating to diabetes. It is not clear whether they have beneficial effects in otherwise healthy individuals. Safety: GLP-1 agonists are generally safe for most people with minor side effects. However, long-term side effects are not known. 1 Availability: Available Dose: Varies - see Chemical formula: C172H265N43O51 (Liraglutide) as a prescription chart at the end of MW: 3751.262 g/mol medicine.
    [Show full text]
  • Effect of Glucose/Sulfonylurea Interaction on Release of Insulin
    Proc. Nati. Acad. Sci. USA Vol. 76, No. 11, pp. 5901-5904, November 1979 Medical Sciences Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas (glibenclamide) SUAD EFENDIt*, FRANZ ENZMANNf, ANITA NYLtN*, KERSTIN UVNAS-WALLENSTENt, AND ROLF LUFT* *Department of Endocrinology, Karolinska Hospital, 104 01 Stockholm; tDepartment of Pharmacology, Karolinska Institute, 104 01 Stockholm, Sweden; and tHoechst Aktiengesellschaft, Medizinische Abteilung, Frankfurt, West Germany Contributed by Rolf Luft, July 27, 1979 ABSTRACT The effect of a sulfonylurea, glibenclamide, method and separated on CM-cellulose column. The antibodies on the release of insulin, glucagon, and somatostatin was studied produced in our laboratory were used at a final dilution of 1: in the isolated perfused rat pancreas. At concentrations glucose 56,000. Crossreactivity of the antibody was less than 0.01% with of 1.1 mM or less, the drug stimulated somatostatin release, whereas glucagon release, after 2-3 min of increase, was insulin, glucagon, substance P, luliberin, vasopressin, and ox- markedly inhibited. Insulin release was moderately stimulated, ytocin. The antigenic specificity of the antibodies was deter- and maximal release occurred relatively late. A moderate glu- mined by using somatostatin analogues (11). Phosphate buffer cose load (6.7 mM) inhibited glibenclamide-induced release of (0.04 M, pH 7.4) containing 1% bovine serum albumin was used somatostatin, whereas the two in combination exerted an ad- as the diluent for all components in this radioimmunoassay. ditive action on insulin release. Greater glucose loads, which by themselves would stimulate somatostatin release, only Incubations were for 48 hr at 4°C.
    [Show full text]
  • Pharmacokinetics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(12):292-295 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Mini-review: Pharmacokinetics of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor Nermeen Ashoush a,b aClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, British University in Egypt, El- Sherouk city, Cairo 11837, Egypt. bHead of Health Economics Unit, Center for Drug Research and Development (CDRD), Faculty of Pharmacy, British University in Egypt, El-Sherouk city, Cairo 11837, Egypt. _____________________________________________________________________________________________ ABSTRACT The dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral hypoglycemic drugs which have been in clinical use for the past 10 years. The drugs are safe, weight neutral and widely prescribed. There are currently many gliptins approved by FDA, namely sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin with several more in advanced stages of development. The gliptins may possess cardiovascular protective effects and their administration may promote β-cell survival; claims currently being evaluated in clinical and preclinical studies. The gliptins are an optional second-line therapy after metformin; they are generally well tolerated with low risk of hypoglycemia. The various compounds differ with respect to their pharmacokinetic properties; however, their clinical efficacy appears to be similar. The clinical differences between the various compounds
    [Show full text]
  • Journal of Diabetes and Obesity
    Journal of Diabetes and Obesity Research Article Open Access The Different Association between Metformin and Sulfony- lurea Derivatives and the Risk of Cancer May be Confounded by Body Mass Index Catherine E. de Keyser1,2, Loes E. Visser1, Albert Hofman1, Bruno H. Stricker1,2*, Rikje Ruiter1# 1 Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands 2 The Health Care Inspectorate, The Hague, the Netherlands *Corresponding author: Bruno H. Stricker, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Netherlands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] #Submitting author: Rikje Ruiter, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Nether- lands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] Abstract Received date: July 09, 2016 Aim: Several studies in large databases suggest that in comparison to glucose-low- Accepted date: : September 05, 2016 ering sulfonylurea derivatives, metformin is associated with a reduced risk of cancer Publication date: September 12, 2016 in patients with diabetes. As many databases miss relevant confounder data, our objective was to investigate whether the determinants age, body mass index (BMI), alcohol consumption, and renal function were associated with dispensing of either Citation: Stricker, B.H., et al. The Dif- metformin or sulfonylurea derivatives as first drug therapy for type 2 diabetes mel- ferent Association between Metformin and litus while taking into account calendar time. Sulfonylurea Derivatives and the Risk of Methods: We identified 639 incident metformin users and 934 incident sulfonylurea Cancer May be Confounded by Body Mass derivatives users in the Rotterdam Study, a prospective population-based cohort Index.
    [Show full text]
  • An in Vivo Investigation Into the Actions of the Hypothalamic Neuropeptide, QRFP
    An In Vivo Investigation into the Actions of the Hypothalamic Neuropeptide, QRFP A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health Christopher J Cook Faculty of Biology, Medicine and Health School of Medical Sciences 2017 Contents Abstract ........................................................................................................................................... 11 Declaration ........................................................................................................................................ 12 Copyright ........................................................................................................................................... 12 Acknowledgement ............................................................................................................................ 13 Chapter 1 Introduction ................................................................................................. 14 1.1 Energy homeostasis ................................................................................................................ 15 1.2 The control of food intake ...................................................................................................... 16 1.2.1 Peripheral signals regulating food intake .......................................................................... 17 1.2.2 Central aspects of food intake regulation ........................................................................
    [Show full text]
  • Marked Improvement in Glycemic Control with Exenatide on Addition
    Journal of Diabetes Mellitus, 2018, 8, 152-159 http://www.scirp.org/journal/jdm ISSN Online: 2160-5858 ISSN Print: 2160-5831 Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience Salina Esmail1, Sonal Banzal2, Udaya M. Kabadi2,3* 1University of Iowa, Iowa City, IA, USA 2MGM College of Medicine, Indore, India 3Broadlawns Medical Center, Des Moines, IA, USA How to cite this paper: Esmail, S., Banzal, S. Abstract and Kabadi, U.M. (2018) Marked Improve- ment in Glycemic Control with Exenatide on Background: The major effect of Exenatide is attributed to lowering of Addition to Metformin, Sulfonylurea and post-prandial glycemia, whereas insulin glargine mainly improves fasting Insulin Glargine in Type 2 Diabetes Mellitus, glycemia [FPG]. Objective: Therefore, we assessed effect of Exenatide a Real World Experience. Journal of Diabetes Mellitus, 8, 152-159. administration at 6 months and for at 1 year on glycemic control, lipids, body https://doi.org/10.4236/jdm.2018.84015 weight [BW], daily insulin dose and hypoglycemic events. Methods: Records of 164 subjects, 126 men and 38 women administered Exenatide between Received: August 27, 2018 January 2011 and December 2013 are included in this report. Exenatide was Accepted: November 12, 2018 Published: November 15, 2018 initiated at 5 mcg subcutaneously twice daily [BID] in obese subjects, BMI > 30 kg/m2, with C-peptide > 1 ng/d, and HbA1c 7.5% - 9.5%, while receiving Copyright © 2018 by authors and daily metformin 2000 mg, Sulfonylurea Glimepiride 8 mg and insulin Glar- Scientific Research Publishing Inc.
    [Show full text]
  • Diabetes in the Elderly: Matching Meds to Needs
    Barbara Keber, MD; Jennifer Fiebert, PharmD Hofstra Northwell School of Diabetes in the elderly: Medicine, Northwell Health, Glen Cove, NY Matching meds to needs [email protected] The authors reported no Elderly patients, whose insulin resistance is complicated potential conflict of interest relevant to this article. by age-related loss of beta-cell function and concomitant diseases, require personalized Tx considerations. s members of the baby boomer generation (adults PRACTICE ≥65 years) age, the number of people at risk for dia- RECOMMENDATIONS betes increases. Already nearly one-quarter of people ❯ Allow higher A1C goals for A 1 over age 65 have type 2 diabetes (T2DM). With a proliferation elderly patients who have of new medications to treat diabetes, deciding which ones to such comorbid conditions use in older patients is becoming complex. as cognitive dysfunction, dementia, or cardiovascu- In this article we review the important issues to consider lar or renal disease. B when prescribing and monitoring diabetes medications in older adults. To provide optimal patient-centered care, it’s nec- ❯ Look to metformin first essary to assess comorbid conditions as well as the costs, risks, in most instances if there are no contraindications. and benefits of each medication. Determining appropriate Monitor renal function goals of therapy and selecting agents that minimize the risk of frequently and vitamin B12 hypoglycemia will help ensure safe and effective management levels periodically. B of older patients with diabetes. ❯ Consider glucagon-like peptide-1 receptor agonists for patients who also have What makes elderly patients unique established cardiovascular The pathophysiology of T2DM in the elderly is unique in that disease, or consider starting it involves not just insulin resistance but also age-related loss basal insulin instead of using of beta-cell function, leading to reduced insulin secretion and multiple oral agents.
    [Show full text]
  • Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly
    2106 Diabetes Care Volume 38, November 2015 fi Wayne H.-H. Sheu,1 Ira Gantz,2 Safety and Ef cacy of Omarigliptin Menghui Chen,2 Shailaja Suryawanshi,2 Arpana Mirza,2 Barry J. Goldstein,2 (MK-3102), a Novel Once-Weekly Keith D. Kaufman,2 and Samuel S. Engel2 DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes Diabetes Care 2015;38:2106–2114 | DOI: 10.2337/dc15-0109 OBJECTIVE This study was conducted to determine the optimal dose of omarigliptin, a once- weekly (q.w.) dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of patients with type 2 diabetes and evaluate the long-term safety of that dose. RESEARCH DESIGN AND METHODS In a multicenter, double-blind, 12-week, dose-range finding study, 685 oral antihy- perglycemic agent-na¨ıve or washed-out subjects with type 2 diabetes were random- ized to one of five once-weekly doses of omarigliptin (0.25 mg, 1 mg, 3 mg, 10 mg, or 25 mg) or placebo. The primary efficacy end point was change from baseline in HbA1c, and secondary end points were 2-h postmeal glucose (PMG) and fasting plasma glucose (FPG). Analysis included all patients who received at least one dose of the study medication. Subjects who completed the base study were eligible to enter a 66-week extension study. RESULTS Once-weekly treatment for 12 weeks with omarigliptin provided dose-related reduc- 1Division of Endocrinology and Metabolism, De- partment of Internal Medicine, Taichung Veterans EMERGING TECHNOLOGIES AND THERAPEUTICS tions in HbA , 2-h PMG, and FPG.
    [Show full text]
  • Albiglutide Needs Greater Accuracy from Remaining Shots on Goal
    November 18, 2011 Albiglutide needs greater accuracy from remaining shots on goal Evaluate Vantage Victoza is looking increasingly bullet-proof. Novo Nordisk’s once-daily GLP-1 agonist proved superior to GlaxoSmithKline’s once-weekly version, albiglutide, in reducing blood glucose while also showing significant weight loss advantages in type II diabetics. This follows a similar win for Victoza against Amylin Pharmaceuticals’ once-weekly challenger in Bydureon (Amylin scores own goal in Bydureon vs Victoza head-to- head study, March 3, 2011). Albiglutide still has a number of shots on goal – data this week from the Harmony 7 trial was the first from eight phase III studies all nearing completion – with a head-to-head against Merck & Co’s DPP-IV inhibitor Januvia probably the most significant in terms of determining albiglutide’s future role and potential in the diabetes market. Although expectations have never been that high, Glaxo’s product had an opportunity to capitalise on the setbacks to Byetta, Bydureon and Roche’s once-weekly taspoglutide – this first trial read out suggests that opportunity will be limited at best or missed altogether. Playing catch up Glaxo’s decision almost three years ago to embark on an extensive phase III programme for albiglutide, branded Syncria at the time, was seen as a bit of a gamble (Glaxo makes brave decision with phase III trials for Syncria, February 17, 2009). Safety concerns about Amylin’s twice-daily Byetta, the only approved GLP-1 agonist at the time, and the fact albiglutide had a lot of ground to make up on Bydureon and taspoglutide, suggested an uphill struggle for Glaxo’s product which was licensed from Human Genome Sciences in 2004.
    [Show full text]
  • Liraglutide for the Treatment of Diabetes Mellitus in Japan
    REVIEW Liraglutide for the treatment of diabetes mellitus in Japan Kohei Kaku† A once‑daily 0.9 mg dose of liraglutide administered to Japanese subjects with Type 2 diabetes mellitus provides a significant glycated reduction hemoglobin of 1.5% or more from the baseline with few Points hypoglycemic episodes. Stepwise dose titration by 0.3‑mg increments at intervals of 1 week significantly reduces the frequency of gastrointestinal symptoms. Practice When liraglutide is used in combination with sulfonylurea, dose reduction of sulfonylurea should be considered to avoid a risk of hypoglycemia. A once‑daily 0.9‑mg dose of liraglutide is not always sufficient to suppress bodyweight gain. The use of liraglutide in insulin‑dependent patients should be strictly avoided. The safety of liraglutide is not established in pregnant patients or in pediatric patients. SUMMARY Impaired b‑cell function in Type 2 diabetes mellitus (T2DM) is generally progressive. The commonly used sulfonylureas (SU) lose efficacy over time and are associated with impaired b‑cell function, and undesirable events such as weight gain and hypoglycemia. Thus, there is a strong need to develop antidiabetic agents that control glycemia without weight gain and hypoglycemia, and preserve b‑cell function. Glucagon‑like‑peptide‑1 (GLP‑1) is known to improve glycemic control by enhancement of glucose‑stimulated insulin secretion, preserving b‑cell function, and minimizing hypoglycemia and weight gain. Liraglutide, a human GLP‑1 analog, has recently been approved for use in Japanese patients with T2DM. To assess liraglutide in management of Japanese patients with T2DM, the results of clinical studies in Japan is summarized and also compared with the data from Europe and the USA.
    [Show full text]
  • 125469Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125469Orig1s000 SUMMARY REVIEW Division Director Review 1. Introduction On September 18, 2013 Eli Lilly and Company submitted a Biologics License Application (BLA) for Trulicity under section 351 of the Public Health Service Act. The applicant is seeking to indicate Trulicity as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Trulicity is a solution for injection containing either 0.75 or 1.5 mg of dulaglutide [i.e., a glucagon-like peptide 1 (GLP-1) receptor agonist]. Trulicity is to be administered by subcutaneous injection at once weekly intervals. Once approved, Trulicity will be the fifth GLP-1 agonist indicated for use in the management of patients with type 2 diabetes mellitus in the United States. This document serves as the division director’s memorandum for the application. 2. Background The drug substance in Trulicity is dulaglutide. In this memorandum, I will use Trulicity and dulaglutide interchangeably. Dulaglutide is a homodimer that consists of two identical polypeptide chains linked to each other by a disulfide bond. The polypeptide chain is a fusion protein that consists of a glucagon-like peptide 1 (GLP-1) variant, a linker, and the Fc portion of a human IgG4 variant antibody. The GLP-1 analog portion of dulaglutide is (b) (4) homologous to native human GLP-1 (7-37) (b) (4) (b) (4) Dulaglutide was demonstrated to bind and activate the GLP-1 receptor. The biological effects of endogenous GLP-1 on glucose homeostasis include augmentation of glucose stimulated insulin secretion, inhibition of glucagon release, and delay of gastric emptying.
    [Show full text]
  • Combination Use of Insulin and Incretins in Type 2 Diabetes
    Canadian Agency for Agence canadienne Drugs and Technologies des médicaments et des in Health technologies de la santé CADTH Optimal Use Report Volume 3, Issue 1C Combination Use of Insulin and July 2013 Incretins in Type 2 Diabetes Supporting Informed Decisions This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). The report contains a comprehensive review of the existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time of report preparation. The information in this report is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this document to ensure that its contents are accurate, complete, and up to date as of the date of publication, CADTH does not make any guarantee to that effect. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document or in any of the source documentation.
    [Show full text]